Panel Discussion: Advancing Drug Development in Cardiovascular-Kidney-Metabolic (CKM) Syndrome
- Explore our evolving understanding of the pathophysiology linking cardiovascular, kidney and metabolic disorders
- Identify when and how overlapping CKM phenotypes can be leveraged to design more efficient clinical trials
- Discuss next steps in integrated drug development and regulatory frameworks for CKM components with shared mechanistic drivers